Plasma catecholamine metabolites and treatment response at neuroleptic steady state.
Using either haloperidol or perphenazine in a fixed-dose protocol, plasma free homovanillic acid (HVA) and methoxyhydroxyphenethylglycol (MHPG) were decreased in 37 nonorganic psychotic inpatients at neuroleptic steady state (7-9 days) in comparison with pretreatment values. The data indicate that the magnitude of the decline in HVA and MHPG was associated with treatment response and not with neuroleptic plasma levels.
Bowers
M B
MB
Department of Psychiatry, Yale University School of Medicine, New Haven, CT.
Swigar
M E
ME
Jatlow
P I
PI
Hoffman
F J
FJ
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D006018:Glycols / Q000097:blood*; D006220:Haloperidol / Q000627:therapeutic use*; D006719:Homovanillic Acid / Q000097:blood*; D006801:Humans; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000097:blood*; D008875:Middle Aged; D010546:Perphenazine / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000097:blood / Q000188:drug therapy*
D006018:Glycols; D008734:Methoxyhydroxyphenylglycol; D010546:Perphenazine; D006220:Haloperidol; D006719:Homovanillic Acid